Topic: Opioid

Health officials in San Francisco have identified a new synthetic opioid called cyclorphine following a recent overdose death. The drug is reportedly more potent than fentanyl, resistant to Narcan, and cannot be detected by standard fentanyl test strips, posing a significant new challenge to emergency responders.

Belgium's drug commissioner, Ine van Weymers, warned that 80% of illegal refill vape capsules seized by customs contain dangerous synthetic opioids. This trend poses a severe risk of addiction for children and is part of a broader rise in organized crime and gun violence in European port cities like Antwerp and Rotterdam. The report suggests that Belgium and the Netherlands are increasingly functioning as narco-states.

Historical media clips from Law & Order and ER are used to illustrate how television has been used for vaccine propaganda, specifically regarding measles outbreaks. The discussion shifts to modern vaccine hesitancy following the COVID-19 pandemic and its impact on public health narratives. Additionally, reports on Sublocade suggest that while it helps with opioid withdrawal, it carries its own risks of high-potency addiction.

An ER nurse provides a technical breakdown of Kratom, distinguishing between the alkaloids mitragynine and the more potent 7-hydroxymitragynine (7-OH). While Kratom is a partial opioid agonist, it is distinguished from "opiates" derived directly from the poppy plant. The 7-OH variant is noted for having more severe withdrawal symptoms.

The FDA is launching a "big action" against vape shops selling 7-OH, a synthetic derivative of the kratom plant. Dr. Marty Makary claims the product binds to opioid receptors 13 times more potently than natural kratom and has been linked to teen addiction. The hosts debate the botanical nature of kratom and criticize the FDA for targeting a plant used for centuries in Asia while ignoring other public health crises.

Advil, in partnership with the Morehouse School of Medicine, launches the "Pain Equity Project" to address alleged racial bias in healthcare. The infomercial features "legacy black" physicians discussing myths about black patients' pain tolerance and the "embedded" nature of racism in medicine. The hosts suggest the campaign is a subliminal effort by Pfizer to market opioids like "Embedda" to the black community.

The FDA has approved Dronavix, a new non-addictive alternative to opioids for treating acute pain. While clinical trials compared the drug to placebos and hydrocodone, critics point out that it was only tested on a few hundred people before being cleared for the general population. Medical professionals are being encouraged to monitor real-life data as the medication is introduced to patients with chronic conditions.

The hosts question the sudden prominence of Respiratory Syncytial Virus (RSV) in news cycles, noting it was rarely mentioned a decade ago. In other pharmaceutical news, the Department of Justice has filed a lawsuit against CVS, alleging the pharmacy chain filled unlawful opioid prescriptions and violated the Controlled Substances Act over the past ten years.

McKinsey & Company agreed to pay $650 million to settle federal investigations into its role in "turbocharging" OxyContin sales for Purdue Pharma. The consulting firm accepted responsibility for advising Purdue to target high-volume prescribers, contributing to the national opioid epidemic.

Mexico's former security chief, Genaro Garcia Luna, was sentenced to over 38 years in a U.S. prison for taking bribes from the Sinaloa drug cartel. A federal court in Brooklyn found him guilty of facilitating the very trafficking operations he was tasked with dismantling. The case is linked to broader U.S. efforts to combat the synthetic opioid crisis and dismantle high-level cartel leadership.

Johnson & Johnson reached a $700 million settlement over allegations of misleading consumers about the safety of its talcum-based baby powder. Additionally, the company agreed to pay $150 million to Washington State to settle claims related to its role in the opioid crisis. These settlements follow the multi-billion dollar bankruptcy of Purdue Pharma and the Sackler family's legal battles, highlighting ongoing accountability efforts within the pharmaceutical industry.

Buses from Chicago transported Palestinian supporters to Washington D.C. for solidarity marches. The hosts contrast the high level of organization for foreign conflicts with the lack of public outcry regarding domestic issues like the opioid crisis, homelessness, and failing infrastructure.

An Advil-sponsored infomercial titled "Believe My Pain" addresses systemic pain bias and racism in the medical field. The project, a partnership with the Morehouse School of Medicine, is analyzed as a potential marketing strategy by Pfizer to expand the opioid market into black communities. The use of the word "embedded" in the program is linked to Pfizer's opioid product, Embedda.

The hosts discuss the Netflix series "Painkiller" and the previous show "Dopesick," characterizing them as efforts to whitewash the broader pharmaceutical industry by focusing all blame on the Sackler family. They argue that while the Sacklers were responsible for the opioid crisis, other major companies like Johnson & Johnson have paid significantly larger fines for similar malfeasance that receives less media dramatization.

BioBot Analytics co-founder Newsha Ghaeli describes the company's technology for analyzing sewage to create a global human health database. Originally focused on the opioid epidemic, the system can geolocate drug use and infectious diseases down to specific neighborhoods or buildings. The hosts compare the company's pitch to the Theranos scandal and raise significant privacy concerns regarding the tracking of pharmaceutical and illicit drug consumption.

The Supreme Court has temporarily blocked a $6 billion settlement for Purdue Pharma that would have shielded the Sackler family from future civil lawsuits. The Biden administration objected to the deal's liability protections. The hosts compare the Sacklers to larger pharmaceutical companies like Johnson & Johnson, suggesting the family is being used as a scapegoat for the broader opioid crisis.

One host discusses their ongoing experiment with Kratom, noting that while the FDA warns of its dangers, many people use it to successfully transition off of harder opioids. They clarify that they are not "strung out" but enjoy the "groovy" feeling it provides while watching television. They distinguish between high-quality leaves and the "micro powder" found in head shops.

Kratom, an herbal drug with opioid-like effects, is facing increased regulation and wrongful death lawsuits in the US. While some users report a euphoric boost in energy, others experience significant withdrawal symptoms, stomach issues, and cognitive impairment. One of the hosts shared a personal anecdote about trying a home-bottled version of the product, describing a "pleasant body buzz."

A federal watchdog reports that over $200 billion in COVID relief funds—roughly 17% of the total distributed—was lost to fraudulent claims. The Small Business Administration (SBA) is criticized for lacking safeguards during the rapid injection of money into the economy. Simultaneously, the Justice Department charges 78 defendants in a $2.5 billion Medicare fraud scheme involving unnecessary medical equipment and repackaged HIV medications.

A federal appeals court cleared a bankruptcy deal for Purdue Pharma that shields the Sackler family from future civil lawsuits related to the opioid crisis. As part of the settlement, the family will pay $6 billion and relinquish control of the company. The ruling has been controversial, as it provides legal immunity to the owners of the company primarily blamed for the OxyContin epidemic.